Kazimierz Groen

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Journal: HemaSphere
Published: July 31, 2025

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Journal: Blood advances
Published: May 23, 2025

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Journal: Blood advances
Published: May 23, 2025

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Journal: HemaSphere
Published: March 17, 2025

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Journal: HemaSphere
Published: February 16, 2024

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Journal: HemaSphere
Published: May 11, 2023

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.

Journal: EClinicalMedicine
Published: March 01, 2023

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.

Journal: Blood advances
Published: December 27, 2021
Showing 1-8 of 8

Last Updated: 09/26/2026